Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus SOX vs SOX in first-line HP-positive advanced gastric cancer
ChiCTR2100041935Phase 4Recruiting
- Sponsor
- Baotou Cancer Hospital
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of camrelizumab in gastric cancer (GC) (2 arms), sponsored by Baotou Cancer Hospital. Primary endpoint: Progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2100041935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041935.